Publication Name	World Journal of Radiology
Manuscript ID	32990
Country	Türkiye

Received	2017-02-03 15:32
Peer-Review Started	2017-02-09 14:25
To Make the First Decision	2017-05-23 00:50
Return for Revision	2017-06-12 01:41
Revised	2017-06-24 16:08
Second Decision	2017-07-28 05:05
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-08-02 20:36
Articles in Press	2017-08-02 20:36
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-09-20 02:57
Publish the Manuscript Online	2017-10-13 01:00

ISSN	1949-8470 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
Manuscript Source	Invited Manuscript
All Author List	Gulgun Engin, Serpil Eraslan, Hülya Kayserili, Yersu Kapran, Haluk Akman, Ali Akyuz and Nuri Faruk Aykan
Funding Agency and Grant Number
Corresponding Author	Gulgun Engin, MD, Oncology Institute, Istanbul University, Millet Street, Capa 34390, Istanbul, Türkiye. gengin@istanbul.edu.tr
Key Words	Gastrointestinal stromal tumor; Familial; Germline mutation; Imatinib; Response
Core Tip	Familial gastrointestinal stromal tumor (GIST) with exon 13 germline mutations are extremely rare. Moreover, there are only a few reports describing the response to imatinib in familial GISTs. The data on the role of imatinib in familial GISTs is still limited. Understanding the role of imatinib is important for the appropriate management of mutation positive familial GISTs. It is also crucial to be able to determine the role of specific germline KIT mutations in. We hereby report our findings in consideration of up-to-date information.
Publish Date	2017-10-13 01:00
Citation	Engin G, Eraslan S, Kayserili H, Kapran Y, Akman H, Akyuz A, Aykan NF. Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report. World J Radiol 2017; In press
URL	http://www.wjgnet.com/1949-8470/full/v9/i9/365.htm
DOI	http://dx.doi.org/10.4329/wjr.v9.i9.365

Full Article (PDF)	WJR-9-365.pdf
Full Article (Word)	WJR-9-365.doc
Manuscript File	32990-Review.docx
Answering Reviewers	32990-Answering reviewers.pdf
Audio Core Tip	32990-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	32990-Conflict-of-interest statement.docx
Copyright License Agreement	32990-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	32990-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	32990-Institutional review board statement.pdf
Peer-review Report	32990-Peer-review(s).pdf
Scientific Misconduct Check	32990-Scientific misconduct check.pdf
Scientific Editor Work List	32990-Scientific editor work list.pdf